Randomized Trial of Shenfu Injection for Sepsis-Induced Cardiomyopathy Incidence

A randomized controlled trial of 152 septic ICU patients, conducted by Yaohui Liu, evaluating the effect of early Shenfu Injection administration on the incidence of sepsis-induced cardiomyopathy. The dataset includes patient outcomes such as NT-proBNP levels, hemodynamic parameters, immune inflammatory indicators, and 28-day mortality. The data was last updated on 2026-03 18.

Use Cases

• Analyzing the incidence of sepsis-induced cardiomyopathy based on patient group assignment and primary outcome data.
• Modeling the effect of Shenfu Injection on biomarker levels (NT-proBNP) using the described generalized linear mixed model.
• Comparing secondary outcomes like hemodynamic parameters, organ function, and mortality between treatment and control groups.
• Studying the relationship between septic shock, baseline biomarkers, and the development of cardiac injury in sepsis.

Strengths

• Data originates from a randomized controlled trial, a gold-standard study design.
• Includes results for 152 patients with 76 per group, providing a clear sample size.
• Covers multiple clinical endpoints: primary incidence outcome, biomarkers, hemodynamics, organ function, and mortality.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 691.1 KB, indicating limited scope.

Provenance

Source

Yaohui Liu via figshare.

Collection Method

Data collected from a randomized controlled trial in an ICU setting.

Time Range

Trial period not specified; data reflects patient outcomes within 28 days.

Freshness

Last updated 2026-03-18 07:39:55; freshness should be verified.

Geography

null